PARKINSON’S DISEASE

• Birkmayer JG, et al. Nicotinamide adenine dinucleotide (NADH)--a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta Neurol Scand Suppl. 1993. PMID 8101414.

• Gadol, E., Mestayer, R.F., Grant, R., Grigoryev, Y., Gibson, S.B., and Happel, M. (20029) A Case of Parkinson’s Disease Symptoms Reduction with Intravenous NAD+. A Case Repor tand Lecture Review, 39(1):1-4.

• Kuhn W, et al. Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis. J Neural Transm (Vienna). 1996. PMID 9013405

MULTIPLE SCLEROSIS / AUTOIMMUNE DISEASE

• Tullius, S. G., Biefer, H. R., Li, S., Trachtenberg, A. J., Edtinger, K., Quante, M., Krenzien, F., Uehara, H., Yang, X., Kissick, H. T., Kuo, W. P., Ghiran, I., de la Fuente, M. A., Arredouani, M. S., Camacho, V., Tigges, J. C., Toxavidis, V., El Fatimy, R., Smith, B. D., Vasudevan, A., … ElKhal, A. (2014). NAD+ protects against EAE by regulating CD4+ T-cell differentiation. Nature Communications, 5, 5101. https://doi.org/10.1038/ncomms6101.

DRUG DEPENDENCY AND ALCOHOLISM

• Broom, S L, Mestayer R, et.al. (2014). Society of Neuroscience Convention. Intravenous Administration of Nicotinamide Adenine Dinucleotide Significantly Reduces Self Report Craving Ratings Associated with Opiate and Alcohol Withdrawal. Published 2014. https://www.brplusmdconsultants.com/cravings-study

• Guest J, Grant R, Mori TA, Croft KD (2014) Changes in Oxidative Damage, Inflammation and [NAD(H)] with Age in Cerebrospinal Fluid. PLoS ONE 9(1): e85335. doi:10.1371/journal.pone.0085335.

• O’Hollaren P. Diphosphopyridine nucleotide in the prevention, diagnosis, and treatment of drug addiction. A preliminary report. West. J. Surg. Obstet. Gynecol. 1961;69:213–215. [PubMed] [Google Scholar]

• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278809/

AGE-RELATED DISEASES

• Braidy N, Berg J, Clement J, et al. Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes. Antioxid Redox Signal. 2019;30(2):251-294. doi:10.1089/ars.2017.7269

• Johnson S, Imai SI. NAD + biosynthesis, aging, and disease. F1000Res. 2018;7:132. Published 2018 Feb 1. doi:10.12688/f1000research.12120.1.

NAD ENERGY DEFICIENCY

• Cleary, J. P. (1986). The NAD deficiency diseases. J Orthomol Med, 1(3), 149-157.

​​